Clinical Trials Logo

Clinical Trial Summary

Uterine fibroids, affecting 20-50% of all women ,and are benign tumors that arise from myometrial cells of the uterine smooth muscle tissue. Although most are asymptomatic, fibroids can often cause abnormal uterine bleeding, iron deficiency anemia, pelvic pressure symptoms and pain


Clinical Trial Description

Women with myomatous uteri have an increased number of blood supply which may cause excessive bleeding during myomectomy. The excessive bleeding may result in blood transfusions and prolonged hospital stays. A variety of methods are used to reduce bleeding during myomectomy including preoperative administration of gonadotropin-releasing hormone (GnRH) agonists, uterine artery tourniquet, vaginal misoprostol, intravenous tranexamic acid, intramyometrial injections of bupivacaine plus adrenaline and vasopressin, chemical dissection with Mesna (sodium-2-mercaptoethanesulfonate), perioperative injection of ascorbic acid, and, recently, carbetocin. Currently, there are several strategies for the treatment of fibroids. Still, myomectomy, the surgical removal of myomas, is an important treatment option for symptomatic leiomyomas, especially in women who wish to preserve their uteri.This can be accomplished via laparotomy, laparoscopy or hysteroscopy. Oxytocin is a hormone secreted from the posterior pituitary and exerts its effect on the uterus by producing uterine contractions during labor and delivery. Because of this contractile feature, synthetic oxytocin analogs are used in the treatment of postpartum uterine atony and hemorrhage. Based on its ability to attenuate blood loss, oxytocin has been evaluated in gynecologic procedures, including hysterectomies, myomectomies, and endometrial resections. Although the expression of oxytocin receptors is thought to be strictly related to pregnancy, their presence has been demonstrated in the leiomyomatous uterus. Carbetocin was first introduced to control postpartum hemorrhage, but its manageability and efficacy soon made it an interesting option for gynecologic surgeons. Given its longer half-life compared with oxytocin and its ample bioavailability, carbetocin could represent a very useful tool during myomectomy, administered either intravenously or intramuscularly Following promising reports on the effectiveness of carbetocin in reducing intraoperative blood loss, hemoglobin drop, and need for postoperative blood transfusions. Adrenaline is a potent vasoconstrictive agent that has a high risk of cardiovascular effects if an intravascular instillation is performed. The vasoconstrictive effect of adrenaline on tissue lasts longer than that of vasopressin. Bupivacaine is a local anesthetic that causes vasodilatation at clinical doses, but lower doses appear to cause vasoconstriction. Bupivacaine has shown to have a vasoconstrictive activity in concentrations of ≤ 0.25%, with duration of its action between 4 and 24 h when used for local infiltration. The use of a combination of bupivacaine and low dose of adrenaline in order to minimize the cardiovascular effects of the latest without interfering with the vasoconstrictive effects on haemostasis has been documented. The myometrial injection of adrenaline plus bupivacaine was one of the evaluated methods showing significantly reduced blood loss and shorter duration of surgery compared to placebo ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05986266
Study type Interventional
Source Egymedicalpedia
Contact
Status Completed
Phase Phase 1
Start date February 1, 2023
Completion date September 15, 2023

See also
  Status Clinical Trial Phase
Terminated NCT04073485 - Microwave Ablation for Uterine Fibroids N/A
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Recruiting NCT01239641 - High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Phase 4
Recruiting NCT04748978 - OPPIuM Technique and Myolysis With Diode Laser Dwls N/A
Not yet recruiting NCT04191603 - TWO DİFFERENT ELECTROSURGERY DEVICES AS MONOPOLAR HOOC AND PLASMAKINETIC BIPOLAR SPATULA EFFECTIVENESS DURING COLPOTOMY N/A
Terminated NCT04132349 - Ulipristal Acetate in Symptomatic Uterine Fibroid Phase 4
Completed NCT03412890 - LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Phase 3
Completed NCT03021720 - Satisfaction of Patients With Trans-Arterial Radial Access: Quality of Life in Uterine Fibroid Embolization Trial N/A
Recruiting NCT04209036 - Can 3D Laparoscopy Improve Surgical Performances in Surgeons in Training?
Completed NCT05086770 - Comparison of Pain After Uterine Artery Embolization Using Gelatin Microsphere or Tris-acryl Gelatin Microsphere N/A
Recruiting NCT05416424 - Life Study: Lifestyle Intervention in Fibroid Elimination N/A
Not yet recruiting NCT05695690 - Role of US in Uterine Fibroids in Comparison With MRI Using FIGO Classification
Completed NCT04832906 - UA Versus UAE in Treatment of Fibroids Phase 4
Completed NCT03444987 - The Role of Fibroblast Activation in Uterine Fibroid
Active, not recruiting NCT06244251 - Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids N/A
Not yet recruiting NCT03450421 - Safety and Efficacy of Actamax™Adhesion Barrier in Women Undergoing Laparoscopic Abdominopelvic Surgery/Myomectomy N/A
Not yet recruiting NCT05840042 - Epidemiology and Risk Factors of Uterine Fibroids in China
Completed NCT04345003 - MR Elastography Parameters Impact on MR-HIFU Efficacy in Uterine Fibroids N/A
Recruiting NCT03118037 - Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry
Completed NCT03103087 - LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Phase 3